Cubist gets fast-track status in 2 areas for antibiotic combo

05/8/2013 | American City Business Journals

The FDA granted fast-track status to Cubist Pharmaceuticals' late-stage antibiotic CXA-201, a combination of ceftolozane and tazobactam, as a treatment for hospital-acquired bacterial pneumonia and complicated urinary tract infections. The antibiotic, which already received a fast-track designation for complicated intra-abdominal infections, is in two Phase III trials for the urinary and abdominal indications. Cubist plans to initiate another late-stage trial against ventilator-associated pneumonia in the coming months.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC